Company: RGNT
Filing Date: 2025-02-12
Form Type: DRS/A
Source: 0001213900-25-012299
Chunk: 148

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-02-12
Form: DRS/A
Chunk 148
---
                    |     | Age |     | Position                |
| Dr. Ehud Geller         |     |  78 |     | Director, Chairman      |
| Mr. Jeff Dykan          |     |  65 |     | Director                |
| Mr. Keith Valentine     |     |  56 |     | Director(1)             |
| Dr. Eli Hazum           |     |  76 |     | Chief Executive Officer |
| Mr. Arie ‌ Gordashnikov |     |  41 |     | Chief Financial Officer |
| Efraim Cohen-Arazi      |     |  68 |     | Director Nominee(1)     |
| Mr. Pini Ben-Elazar     |     |  52 |     | Director Nominee(1)(2)  |
| Dr. Susan Alpert        |     |  76 |     | Director Nominee(1)(2)  |

| (1) | Indicates an Independent Director and a member of our Audit Committee and Compensation Committee. |

| (2) | Each of Mr. Ben-Elazar and Dr. Alpert will become a director at the                                                                       
 effective time of the registration statement to which this prospectus relates, and will serve as an external director under the Companies 
 Law subject to the ratification of his/her appointment at a general meeting of our shareholders to be held following the completion of    
 this offering.                                                                                                                            |

Dr. Ehud Geller, Chairman of the Board of Directors

Dr.
Ehud Geller has served as the Chairman of our Board of Directors since 2007. Since 1995, Dr. Geller has served as the General Partner
of Medica Venture Partners. Between 1979 and 1985, Dr. Geller was President of the Pharmaceutical Division of Teva Pharmaceutical
Industries Ltd. (NYSE:TEVA) and Executive VP of the Teva Group. At Teva, he led the acquisition of Ikapharm Ltd. He served as the President
and Chief Executive Officer of Interpharm Laboratories, Ltd. from 1985 to 1990. During these years he also served as head of the Israeli
Pharmaceutical Manufacturers Association and as a Board Member on the Tel Aviv Stock Exchange. Dr. Geller has a B.Sc. degree in Chemical
Engineering, an MBA degree from Columbia University/Drexel Institute and a Ph.D. degree in Pharmaceutical/Chemical Engineering from Drexel